John Newman
Stock Analyst at Canaccord Genuity
(2.09)
# 2,682
Out of 4,670 analysts
81
Total ratings
44.44%
Success rate
-9.23%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $171 | $113.13 | +51.15% | 7 | Nov 18, 2024 | |
| MCRB Seres Therapeutics | Maintains: Buy | $10 | $0.77 | +1,201.07% | 9 | Nov 14, 2024 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $13 → $21 | $11.47 | +83.09% | 3 | Nov 13, 2024 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $9.76 | +115.16% | 1 | Oct 18, 2024 | |
| ACLX Arcellx | Maintains: Buy | $85 → $115 | $90.44 | +27.16% | 8 | Oct 17, 2024 | |
| ACET Adicet Bio | Maintains: Buy | $19 → $8 | $0.90 | +788.89% | 6 | Sep 11, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $35 → $14 | $2.21 | +533.48% | 2 | Aug 8, 2024 | |
| MRUS Merus | Maintains: Buy | $67 | $45.49 | +47.29% | 2 | Jul 25, 2024 | |
| RNAC Cartesian Therapeutics | Maintains: Buy | $38 → $43 | $18.87 | +127.87% | 1 | Jul 3, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,152 | $738.00 | +56.10% | 15 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $6 | $0.19 | +3,057.89% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $3.61 | +204.71% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.95 | +424.05% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $55.68 | -20.98% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $86 → $20 | $0.35 | +5,612.65% | 4 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $380 → $100 | $2.47 | +3,948.58% | 2 | Apr 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $220 | $5.17 | +4,155.32% | 3 | Jun 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $17.36 | +118.89% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $4.85 | +456.70% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $8.86 | - | 1 | Sep 13, 2017 |
BioNTech SE
Nov 18, 2024
Maintains: Buy
Price Target: $171
Current: $113.13
Upside: +51.15%
Seres Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $10
Current: $0.77
Upside: +1,201.07%
Atara Biotherapeutics
Nov 13, 2024
Maintains: Buy
Price Target: $13 → $21
Current: $11.47
Upside: +83.09%
Delcath Systems
Oct 18, 2024
Maintains: Buy
Price Target: $21
Current: $9.76
Upside: +115.16%
Arcellx
Oct 17, 2024
Maintains: Buy
Price Target: $85 → $115
Current: $90.44
Upside: +27.16%
Adicet Bio
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.90
Upside: +788.89%
Allogene Therapeutics
Aug 8, 2024
Maintains: Buy
Price Target: $35 → $14
Current: $2.21
Upside: +533.48%
Merus
Jul 25, 2024
Maintains: Buy
Price Target: $67
Current: $45.49
Upside: +47.29%
Cartesian Therapeutics
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $18.87
Upside: +127.87%
Regeneron Pharmaceuticals
Jun 27, 2024
Maintains: Buy
Price Target: $1,152
Current: $738.00
Upside: +56.10%
May 16, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.19
Upside: +3,057.89%
May 9, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $3.61
Upside: +204.71%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.95
Upside: +424.05%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $55.68
Upside: -20.98%
Aug 10, 2021
Downgrades: Hold
Price Target: $86 → $20
Current: $0.35
Upside: +5,612.65%
Apr 9, 2019
Maintains: Buy
Price Target: $380 → $100
Current: $2.47
Upside: +3,948.58%
Jun 13, 2018
Maintains: Buy
Price Target: $210 → $220
Current: $5.17
Upside: +4,155.32%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $17.36
Upside: +118.89%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $4.85
Upside: +456.70%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $8.86
Upside: -